{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:40:08Z","timestamp":1744494008313,"version":"3.40.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40121-025-01132-3","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T02:01:46Z","timestamp":1743386506000},"page":"819-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Evaluation of Adolescent Vaccination with Serogroup ACWY and C Meningococcal Vaccines in Germany"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-650X","authenticated-orcid":false,"given":"Sebastian","family":"Gruhn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4445-965X","authenticated-orcid":false,"given":"Manuel","family":"Batram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3032-6354","authenticated-orcid":false,"given":"Moritz","family":"Wick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Langevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-8829","authenticated-orcid":false,"given":"Stefan","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9552-6969","authenticated-orcid":false,"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0261-3655","authenticated-orcid":false,"given":"Oliver","family":"Damm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"1132_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fped.2018.00321","volume":"6","author":"S Nadel","year":"2018","unstructured":"Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321. https:\/\/doi.org\/10.3389\/fped.2018.00321.","journal-title":"Front Pediatr"},{"key":"1132_CR2","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","volume":"22","author":"J Shen","year":"2022","unstructured":"Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application\u2014a systematic and clinical review. BMC Public Health. 2022;22:1078. https:\/\/doi.org\/10.1186\/s12889-022-13342-2.","journal-title":"BMC Public Health"},{"key":"1132_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228020","volume":"15","author":"L Huang","year":"2020","unstructured":"Huang L, Heuer OD, Jan\u00dfen S, et al. Clinical and economic burden of invasive meningococcal disease: evidence from a large German claims database. PLoS ONE. 2020;15: e0228020. https:\/\/doi.org\/10.1371\/journal.pone.0228020.","journal-title":"PLoS ONE"},{"key":"1132_CR4","unstructured":"European Centre for Disease Prevention and Control (2024) Invasive meningococcal disease. Annual epidemiological report for 2022., Stockholm"},{"key":"1132_CR5","unstructured":"Robert Koch-Institut SurvStat@RKI 2.0: Web-basierte Abfrage der Meldedaten gem\u00e4\u00df Infektionsschutzgesetz (IfSG)"},{"key":"1132_CR6","unstructured":"Robert Koch-Institut (2016) \"Invasive Meningokokken- Erkrankungen 2012\u2009\u2013\u20092015\". RKI-Bib1 (Robert Koch-Institut)"},{"key":"1132_CR7","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.vaccine.2022.02.043","volume":"40","author":"S Gruhn","year":"2022","unstructured":"Gruhn S, Witte J, Greiner W, et al. Epidemiology and economic burden of meningococcal disease in Germany: a systematic review. Vaccine. 2022;40:1932\u201347. https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.043.","journal-title":"Vaccine"},{"key":"1132_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2807\/1560-7917.ES.2019.24.14.1800245","volume":"24","author":"M Krone","year":"2019","unstructured":"Krone M, Gray S, Abad R, et al. Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017. Euro Surveill. 2019;24:8. https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.14.1800245.","journal-title":"Euro Surveill"},{"key":"1132_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2807\/1560-7917.ES.2022.27.3.2002075","volume":"27","author":"C Nuttens","year":"2022","unstructured":"Nuttens C, Findlow J, Balmer P, et al. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Euro Surveill. 2022;27:9. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.3.2002075.","journal-title":"Euro Surveill"},{"key":"1132_CR10","doi-asserted-by":"publisher","first-page":"1000657","DOI":"10.3389\/fped.2022.1000657","volume":"10","author":"G Pinto Cardoso","year":"2022","unstructured":"Pinto Cardoso G, Lagr\u00e9e-Chastan M, Caseris M, et al. Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries. Front Pediatr. 2022;10:1000657. https:\/\/doi.org\/10.3389\/fped.2022.1000657.","journal-title":"Front Pediatr"},{"key":"1132_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","volume":"116","author":"F Martin\u00f3n-Torres","year":"2022","unstructured":"Martin\u00f3n-Torres F, Taha M-K, Knuf M, et al. Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations. Pathog Glob Health. 2022;116:85\u201398. https:\/\/doi.org\/10.1080\/20477724.2021.1972663.","journal-title":"Pathog Glob Health"},{"key":"1132_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2352-4642(21)00335-7","volume":"6","author":"H Campbell","year":"2022","unstructured":"Campbell H, Andrews N, Parikh SR, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6:96\u2013105. https:\/\/doi.org\/10.1016\/S2352-4642(21)00335-7.","journal-title":"Lancet Child Adolesc Health"},{"key":"1132_CR13","doi-asserted-by":"publisher","first-page":"1649.e1","DOI":"10.1016\/j.cmi.2022.07.004","volume":"28","author":"JP Carr","year":"2022","unstructured":"Carr JP, MacLennan JM, Plested E, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28:1649.e1-1649.e8. https:\/\/doi.org\/10.1016\/j.cmi.2022.07.004.","journal-title":"Clin Microbiol Infect"},{"key":"1132_CR14","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1093\/cid\/ciab791","volume":"74","author":"M Ohm","year":"2022","unstructured":"Ohm M, Hahn\u00e9 SJM, van der Ende A, et al. Vaccine impact and effectiveness of meningococcal serogroup ACWY conjugate vaccine implementation in the Netherlands: a nationwide surveillance study. Clin Infect Dis. 2022;74:2173\u201380. https:\/\/doi.org\/10.1093\/cid\/ciab791.","journal-title":"Clin Infect Dis"},{"key":"1132_CR15","doi-asserted-by":"publisher","unstructured":"Robert Koch-Institut (2024) Empfehlung zur Standardimpfung von S\u00e4uglingen gegen Meningokokken der Serogruppe B und die dazugeh\u00f6rige wissenschaftliche Begr\u00fcndung. https:\/\/doi.org\/10.25646\/11900","DOI":"10.25646\/11900"},{"key":"1132_CR16","unstructured":"Griskaitis M, Sch\u00f6nfeld V, G\u00fcnther F et al. (2024) AMSeC - Auffrischimpfung gegen Meningokokken der Serogruppe C: Absch\u00e4tzung der Effekte auf Krankheitslast und Kosten im deutschen Gesundheitssystem: Ergebnisbericht"},{"key":"1132_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","volume":"34","author":"B Ultsch","year":"2016","unstructured":"Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34:227\u201344. https:\/\/doi.org\/10.1007\/s40273-015-0335-2.","journal-title":"Pharmacoeconomics"},{"key":"1132_CR18","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40121-024-00958-7","volume":"13","author":"S Gruhn","year":"2024","unstructured":"Gruhn S, Batram M, Wick M, et al. Modelling the public health impact of MenACWY and MenC adolescent vaccination strategies in Germany. Infect Dis Ther. 2024;13:907\u201320. https:\/\/doi.org\/10.1007\/s40121-024-00958-7.","journal-title":"Infect Dis Ther"},{"key":"1132_CR19","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","volume":"34","author":"H Lecocq","year":"2016","unstructured":"Lecocq H, Du Parent CI, Taha M-K, et al. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34:2240\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.020.","journal-title":"Vaccine"},{"key":"1132_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jinf.2012.09.008","volume":"66","author":"W Hellenbrand","year":"2013","unstructured":"Hellenbrand W, Elias J, Wichmann O, et al. Epidemiology of invasive meningococcal disease in Germany, 2002\u20132010, and impact of vaccination with meningococcal C conjugate vaccine. J Infect. 2013;66:48\u201356. https:\/\/doi.org\/10.1016\/j.jinf.2012.09.008.","journal-title":"J Infect"},{"key":"1132_CR21","unstructured":"Stouthard ME, Essink-Bot M-L, Bonsel GJ et al. (1997) Disability weights for diseases in the Netherlands. Inst. Sociale Geneeskunde, Amsterdam"},{"key":"1132_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10198-004-0264-z","volume":"6","author":"W Greiner","year":"2005","unstructured":"Greiner W, Claes C, Busschbach JJV, et al. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124\u201330. https:\/\/doi.org\/10.1007\/s10198-004-0264-z.","journal-title":"Eur J Health Econ"},{"key":"1132_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/hec.1124","volume":"15","author":"LM Lamers","year":"2006","unstructured":"Lamers LM, McDonnell J, Stalmeier PFM, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006;15:1121\u201332. https:\/\/doi.org\/10.1002\/hec.1124.","journal-title":"Health Econ"},{"key":"1132_CR24","unstructured":"Statistisches Bundesamt (2023) Sterbetafeln. https:\/\/www-genesis.destatis.de\/genesis\/online?sequenz=statistikTabellen&selectionname=12621"},{"key":"1132_CR25","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/j.jval.2022.09.519","volume":"25","author":"J Witte","year":"2022","unstructured":"Witte J, Gruhn S, Wick M, et al. EE271 health state utility values used in economic evaluation of meningococcal vaccination: a systematic review. Value in Health. 2022;25:S107. https:\/\/doi.org\/10.1016\/j.jval.2022.09.519.","journal-title":"Value in Health"},{"key":"1132_CR26","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","volume":"37","author":"S Scholz","year":"2019","unstructured":"Scholz S, Koerber F, Meszaros K, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37:1692\u2013701. https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.013.","journal-title":"Vaccine"},{"key":"1132_CR27","unstructured":"Statistisches Bundesamt (2023) Verbraucherpreisindex: Deutschland, Jahre. https:\/\/www-genesis.destatis.de\/genesis\/\/online?operation=table&code=61111-0001"},{"key":"1132_CR28","unstructured":"Statistik der Bundesagentur f\u00fcr Arbeit (2020) Berichte: Analyse Arbeitsmarkt. Gemeldete Arbeitsstellen (Monatszahlen). Januar 2020., N\u00fcrnberg"},{"key":"1132_CR29","unstructured":"LAUER-FISCHER GmbH (2023) LAUER-TAXE\u00ae"},{"key":"1132_CR30","unstructured":"Rieck T, Feig M, Siedler A (2022) Impfquoten von Kinderschutzimpfungen in Deutschland \u2013 aktuelle Ergebnisse aus der RKI-Impfsurveillance. Epidemiologisches Bulletin:3\u201325"},{"key":"1132_CR31","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","volume":"384","author":"RC Read","year":"2014","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet. 2014;384:2123\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(14)60842-4.","journal-title":"Lancet"},{"key":"1132_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1086\/527401","volume":"197","author":"MCJ Maiden","year":"2008","unstructured":"Maiden MCJ, Ibarz-Pav\u00f3n AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737\u201343. https:\/\/doi.org\/10.1086\/527401.","journal-title":"J Infect Dis"},{"key":"1132_CR33","unstructured":"St\u00e4ndige Impfkommission (2024) Modelling methods for predicting epidemiological and health economic effects of vaccinations \u2013 Guidance for analyses to be presented to the German Standing Committee on Vaccination (STIKO), Berlin"},{"key":"1132_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","volume":"21","author":"H Christensen","year":"2020","unstructured":"Christensen H, Al-Janabi H, Levy P, et al. Economic evaluation of meningococcal vaccines: considerations for the future. Eur J Health Econ. 2020;21:297\u2013309. https:\/\/doi.org\/10.1007\/s10198-019-01129-z.","journal-title":"Eur J Health Econ"},{"key":"1132_CR35","doi-asserted-by":"publisher","DOI":"10.1017\/s0950268823000870","volume":"151","author":"L Hadley","year":"2023","unstructured":"Hadley L, Karachaliou Prasinou A, Christensen H, et al. Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK. Epidemiol Infect. 2023;151: e98. https:\/\/doi.org\/10.1017\/s0950268823000870.","journal-title":"Epidemiol Infect"},{"key":"1132_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, et al. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup b invasive meningococcal disease. Infect Dis Ther. 2022;11:367\u201387. https:\/\/doi.org\/10.1007\/s40121-021-00573-w.","journal-title":"Infect Dis Ther"},{"key":"1132_CR37","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(\u00ae) to reduce meningococcal group B disease in Germany. Vaccine. 2016;34:3412\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.004.","journal-title":"Vaccine"},{"key":"1132_CR38","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382:318\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1900236.","journal-title":"N Engl J Med"},{"key":"1132_CR39","doi-asserted-by":"publisher","first-page":"7558","DOI":"10.1016\/j.vaccine.2020.08.007","volume":"38","author":"E Beck","year":"2020","unstructured":"Beck E, Klint J, Garcia S, et al. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: an application to England. Vaccine. 2020;38:7558\u201368. https:\/\/doi.org\/10.1016\/j.vaccine.2020.08.007.","journal-title":"Vaccine"},{"key":"1132_CR40","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, van Exel J, Brouwer W, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25:1529\u201344. https:\/\/doi.org\/10.1002\/hec.3259.","journal-title":"Health Econ"},{"key":"1132_CR41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91\u2013104. https:\/\/doi.org\/10.1016\/j.jval.2020.09.004.","journal-title":"Value Health"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01132-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01132-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01132-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T21:20:21Z","timestamp":1744492821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01132-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1132"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01132-3","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"9 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Moritz Wick, Edith Langevin, and Oliver Damm are Sanofi employees and may hold shares and\/or stock options in the company. Sebastian Gruhn, Manuel Batram, Stefan Scholz, and Wolfgang Greiner received research grants from Sanofi-Aventis Deutschland GmbH. All authors declare no other financial or nonfinancial relationships and activities. Stefan Scholz has changed affiliation after the completion of the manuscript and is now an employee of Moderna Germany GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}